Nitric oxide in the COPD pathogenesis in patients with pulmonary tuberculosis Source: International Congress 2019 – Oxidative stress, hypoxia and microbial exposure in the pathogenesis of pulmonary disease Year: 2019
Nitric oxide in acute testing in patients with pulmonary hypertension Source: Eur Respir J 2004; 24: Suppl. 48, 277s Year: 2004
Is arginase a potential drug target in tobacco-induced pulmonary endothelial dysfunction? Source: International Congress 2015 – Pulmonary hypertension: promising small molecules Year: 2015
Factors associated with severity of pulmonary tuberculosis and mortality in TB patients with diabetes mellitus Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014
Newly detected pulmonary tuberculosis in patients combined with diabetes mellitus and without it. Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019
Clinical characteristics and outcomes of pulmonary tuberculosis in patients with diabetes mellitus Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Clinical features of pulmonary tuberculosis in patients with diabetes mellitus Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012
Comparison of the clinical manifestations of tuberculosis in patients with different type’s of diabetes mellitus and without it Source: International Congress 2016 – Tuberculosis: the elderly, the diabetic, the unusual, and the severe Year: 2016
Nitric oxide, TNF-α and IFN-γ receptor in MDR-TB patients: a follow-up study Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007
Gene polymorphisms of endothelial nitric oxide synthase in pulmonary arterial hypertension Source: Annual Congress 2005 - Pulmonary hypertension: pathophysiology Year: 2005
Impact of diabetes mellitus on clinical parameters and treatment outcomes of diagnosed pulmonary tuberculosis patients Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014
Clinical manifestations and efficacy MDR/XDR tuberculosis in patients with different type’s of diabetes mellitus Source: International Congress 2015 – Case series and clinical conundrums in TB Year: 2015
Physical training and metabolics of nitric oxide in individuals with idiopathic pulmonary arterial hypertension. Source: International Congress 2019 – Exercise tolerance and its determinants across pathologies Year: 2019
Riociguat for the treatment of pulmonary arterial hypertension (PAH): A responder analysis from the phase III PATENT-1 study Source: Annual Congress 2013 –Pulmonary circulation: treatment Year: 2013
Treatment effectiveness among patients with newly detected pulmonary tuberculosis with diabetes mellitus comorbidity Source: Eur Respir J 2004; 24: Suppl. 48, 653s Year: 2004
Vasoreactivity to inhaled nitric oxide does not predict long term survival in pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: the clinic I Year: 2016
Radiological features of pulmonary tuberculosis in patients with diabetes mellitus Source: Annual Congress 2011 - Management of tuberculosis Year: 2011
The cycle of the nitric oxide metabolism in patients with COPD and chronic cerebrovascular diseases (CCVD) Source: Annual Congress 2013 –The vulnerable patient and ageing cells Year: 2013
Pulmonary tuberculosis and diabetes mellitus Source: Eur Respir J 2006; 28: Suppl. 50, 506s Year: 2006
Influence of diabetes mellitus on sputum conversion rate in pulmonary tuberculosis and on antituberculous drug resistance Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019